Antisense Drugs

Company updates positive clinical data on multiple antisense drugs

Published in Gene Therapy Weekly, December 4th, 2003

Isis Pharmaceuticals, Inc., (ISIS) announced positive data from clinical trials of four antisense drugs for the treatment of four diseases.

Final results from phase II studies of ISIS 104838 in patients with rheumatoid arthritis and ISIS 14803 for the treatment of the hepatitis C virus (HCV) were presented at the 67th annual meeting of the American College of Rheumatology and the 54th annual meeting of the American Association for the Study of Liver Diseases, respectively.

Updated results of a phase II study of alicaforsen (ISIS 2302) in patients with pouchitis were presented at the 67th annual scientific meeting of the American College of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-12-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry